Prescription medicine
Alogliptin Brand names: Nesina
Alogliptin (Nesina) is a prescription medicine with an FDA approval on record since 2013. No generic is listed; pharmacies paid $4.96 per alogliptin 12.5 mg tablet in the October 7, 2026 NADAC survey.
- No generic listed
Check it at the source: the alogliptin FDA label on DailyMed (effective February 28, 2025, Takeda Pharmaceuticals America, Inc.); the NDA 22271 record on Drugs@FDA; every alogliptin label on DailyMed.
Highlights of the record
FDA label of February 28, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageNESINA ® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Forms and strengths
- 6.25 mg
- 12.5 mg
- 25 mg
Film-coated tablet.
On the market
- Earliest approval on file
- January 25, 2013 Nesina, Takeda Pharms Usa; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 5 of which 0 under generic applications, 1 under brand applications, repackagers included
- Last listed patent
- June 16, 2029 Nesina tablets; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- $4.96 per tablet Alogliptin 12.5 mg tablet
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 3,409 through July 30, 2026
What is alogliptin used for?
From the label: indications and usageNESINA ® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. NESINA is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) Limitations of Use: Should not be used in patients with type 1 diabetes mellitus. ( 1 ) Limitations of Use NESINA is not recommended for use in patients with type 1 diabetes mellitus.
Conditions named in the indications of alogliptin's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Dipeptidyl Peptidase 4 Inhibitor.
Source: FDA drug label (Nesina), Takeda Pharmaceuticals America, Inc., effective February 28, 2025 (SPL set a3768c7e-aa4c-44d3-bc53-43bb7346c0b0), via openFDA; the full label on DailyMed
What does the patient leaflet for alogliptin say first?
The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.
From the patient leaflet: What is the most important information I should know about NESINA?Serious side effects can happen to people taking NESINA, including: 1. Inflammation of the pancreas (pancreatitis): NESINA may cause pancreatitis which may be severe. Certain medical conditions make you more likely to get pancreatitis. Before you start taking NESINA: Tell your doctor if you have ever had: pancreatitis high blood triglyceride levels kidney problems stones in your gallbladder (gall stones) liver problems a history of alcoholism Stop taking NESINA and call your doctor right away if you have pain in your stomach area (abdomen) that is severe and will not go away. The pain may be felt going from your abdomen through to your back. The pain may happen with or without vomiting. These may be symptoms of pancreatitis. 2. Heart failure: Heart failure means your heart does not pump blood well enough. Before you start taking NESINA: Tell your doctor if you have ever had heart failure or have problems with your kidneys. Contact your doctor right away if you have any of the following symptoms: increasing shortness of breath or trouble breathing especially when lying down an unusually fast increase in weight swelling of feet, ankles, or legs unusual tiredness These may be symptoms of heart failure.
From the patient leaflet: How should I store NESINA?Store NESINA at room temperature between 68°F to 77°F (20°C to 25°C). Keep NESINA and all medicines out of the reach of children.
Source: FDA drug label (Nesina), Takeda Pharmaceuticals America, Inc., effective February 28, 2025 (SPL set a3768c7e-aa4c-44d3-bc53-43bb7346c0b0), via openFDA; the full label on DailyMed
Is there a generic for alogliptin (Nesina)?
No generic alogliptin is approved (Drugs@FDA, October 8, 2026). Drugs@FDA also holds 2 tentative approvals: the FDA found the generic approvable, but patents or exclusivity keep it from final approval for now.
The Orange Book lists 2 patents for Nesina tablets: the compound patent runs to June 27, 2028, and the last listed entry to June 16, 2029. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2013 earliest approval on file
- 2029 last listed patent
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for alogliptin (Nesina)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $4.96 per Alogliptin 12.5 mg tablet, up 9% from $4.54 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Alogliptin 25 mg tablet (generic)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Alogliptin 12.5 mg tablet | Generic | $4.96 per tablet | $148.70 | +9% |
| Alogliptin 25 mg tablet | Generic | $4.91 per tablet | $147.21 | +6% |
| Alogliptin 6.25 mg tablet | Generic | $5.28 per tablet | $158.35 | +5% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What do FAERS reports show for alogliptin?
The FDA Adverse Event Reporting System holds 3,409 reports that list alogliptin among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 357 are coded as a death and 1,568 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as alogliptin?
31 other medicines are given the same way (oral) and in the same FDA class as alogliptin or labeled mainly for the same use (type 2 diabetes), the same class first. Type 2 diabetes lists all 52 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Metformin and sitagliptin | Type 2 diabetes | 4 labelers | $1.76 per tablet 50 mg-1,000 mg tablet | No current entry |
| Sitagliptin | Type 2 diabetes | 4 labelers | $3.77 per tablet 100 mg tablet | No current entry |
| Linagliptin and metformin | Type 2 diabetes | 1 labeler | $8.44 per tablet 2.5 mg-1,000 mg tablet | No current entry |
| Metformin and saxagliptin | Type 2 diabetes | 2 labelers | $9.65 per tablet 5-1,000 mg tablet | No current entry |
| Saxagliptin | Type 2 diabetes | 3 labelers | $1.04 per tablet 5 mg tablet | No current entry |
| Empagliflozin and linagliptin and metformin | Type 2 diabetes | none listed | $11.28 per tablet 10-5-1,000 mg tablet | No current entry |
| Linagliptin | Type 2 diabetes | none listed | $16.80 per tablet 5 mg tablet | No current entry |
| Empagliflozin and linagliptin | Type 2 diabetes | none listed | $11.24 per tablet 10 mg-5 mg tablet | No current entry |
Every medicine labeled for the same conditions as alogliptin
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
How does alogliptin compare with medicines for the same use?
3 side-by-side pages set alogliptin beside a medicine whose label shares a use: approvals, generics, pharmacy cost, warnings and supply.
What next?
- Alternatives to alogliptin
- 31 medicines for the same use
- Other DPP-4 inhibitors
- the pharmacologic class, with prices and generics
- Alogliptin side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other